Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1691 4100
This examiner grants 47% of resolved cases
Christopher Lindsay Johnson serves in Tech Center 4100 and Art Unit 1691. He has 32 resolved cases and an allowance rate of 46.9 percent. This rate indicates that slightly less than half of the applications result in an allowance. Practitioners should be prepared for a competitive examination process where clear and concise technical arguments are necessary to reach the 46.9 percent threshold.
The interview lift is 81.0 percent. This is an exceptionally high figure, suggesting that interviews are extremely effective with this examiner. An interview may nearly double the 46.9 percent baseline allowance rate, making it an essential strategy for any practitioner. Direct communication appears to be the most successful way to address the examiner's concerns and move an application toward a grant.
The median days to allowance is 1240. This pendency is moderate, representing a reasonable timeline for successful prosecution. Given the 81.0 percent lift, practitioners should prioritize interviews early in the process to maximize the 46.9 percent chance of allowance. This strategy may also help manage the 1240 day timeline by resolving issues more quickly than through written responses alone.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18730491 | HETEROARYL DERIVATIVE AND USES THEREOF | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18565049 | Polymeric Antifouling Coating with Antimicrobial Peptides | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18274560 | METHODS FOR INHIBITING CORONAVIRUSES USING SULFORAPHANE | Non-Final OA | The Johns Hopkins University |
| 18556081 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17775100 | EFFECTIVE INTRANASAL DELIVERY TO BRAIN | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18862344 | USE OF (5S)-3-[3-(3-CHLORO-2-FLUOROPHENOXY)-6-METHYLPYRIDAZIN-4-YL]-5-(2-CHLORO-4-METHYLBENZYL)-5,6-DIHYDRO-4H-1,2,4-OXADIAZINE FOR CONTROLLING UNWANTED MICROORGANISMS | Non-Final OA | Bayer Aktiengesellschaft |
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | Non-Final OA | Juno Therapeutics, Inc. |
| 18007822 | METHODS OF TREATING A CORONAVIRUS INFECTION | Non-Final OA | The General Hospital Corporation |
| 17791770 | STIMULATION OF HAIR GROWTH | Non-Final OA | The General Hospital Corporation |
| 18145595 | UREA INHIBITORS OF MICRO-RNA | Non-Final OA | Board of Regents, The University of Texas System |
| 18867521 | EMULSION WITH GLYCERYL CAPRYLATE AND AT LEAST ONE EMOLLIENT CHOSEN FROM MONO, DI AND/OR TRIESTER | Non-Final OA | BEIERSDORF AG |
| 18288131 | COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY | Non-Final OA | Kyoto University |
| 18376498 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Non-Final OA | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization |
| 17414549 | LUMINESCENT SOLAR CONCENTRATOR COMPRISING DITHIENYLPYRIDINETHIADIOAZOLE COMPOUNDS | Final Rejection | ENI S.P.A. |
| 18537780 | CORNEAL THERAPY | Non-Final OA | Harrow IP, LLC |
| 18034530 | COMPOUND CONTAINING 2,4-THIAZOLE RING, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | SHANDONG UNIVERSITY |
| 17923803 | METHODS OF MONITORING KRAS MUTATIONS | Non-Final OA | Cardiff Oncology, Inc. |
| 18105460 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | Final Rejection | Ascendis Pharma A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy